Global Interventional Tumor Ablation Market Size, Share, and COVID-19 Impact Analysis, By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Others), By Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033.

Global Interventional Tumor Ablation Market Insights Forecasts to 2033

• The Global Interventional Tumor Ablation Market Size Was Estimated at USD 1.82 Billion in 2023
• The Market Size is expected to grow at a CAGR of around 9.30% from 2023 to 2033 
• The Worldwide Interventional Tumor Ablation Market Size is Expected to Reach USD 4.43 Billion by 2033 
• Asia Pacific is Expected to Grow the fastest during the forecast period.   

The Global Interventional Tumor Ablation Market Size was valued at USD 1.82 Billion in 2023 and is expected to reach USD 4.43 Billion by 2033, Growing at a CAGR of 9.30% from 2023 to 2033. The global market of interventional tumor ablation is driven by the growing interest in radiofrequency, microwave, and cryoablation. As a result, both patients and medical professionals are starting to choose these less intrusive procedures. Tumor ablation techniques, which can enhance patient outcomes with shorter hospital stays, are in perfect harmony with this trend. Technological advancements in ablation devices and imaging processes. As well as changing consumer preferences, and an increasing emphasis on sustainable practices.  

Market Overview

The interventional tumor ablation industry refers to the market for therapies that eliminate tumor cells by using heat, ice, or sound waves.  These therapies are used to treat lung, kidney, and liver cancer, among other cancers. Tumors can be destroyed or eliminated using a variety of methods without requiring open surgery.  In order to minimize harm to the surrounding healthy tissues, interventional tumor ablation aims to specifically target and eliminate tumor cells.  

The rising number of cancer diseases affected patients due to the consumption of unhealthy foods. So, this rising prevalence of several cancers worldwide. According to World Health Organization data, cancer has become one of the leading causes of death, there were a predicted 20 million new cancer cases and 9.7 million deaths due to cancer in 2023. There is an urgent need for efficient tumor-management treatments with few adverse effects as a result of this predominance.  Patients and healthcare professionals alike like tumor ablation procedures, such as radiofrequency, microwave, and cryoablation, since they provide targeted treatment by eliminating cancer cells with little harm to surrounding tissues.

Moreover, the increasing use of sophisticated imaging methods improves the accuracy of tumor ablation treatments. Methods like ultrasound, MRI, and other diagnosis processes offer immediate direction during ablation, greatly enhancing patient results. The combination of these imaging technologies with ablation procedures has been revolutionary, leading to increased efficacy rates and better results of patient treatment, which helps to drive the industry growth of interventional tumor ablation.

Report Coverage

This research report categorizes the global interventional tumor ablation market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global interventional tumor ablation market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global interventional tumor ablation market.  

Driving Factors

The rising interest in cryoablation, microwave ablation, and radiofrequency ablation. Consequently, individuals and medical experts are beginning to favor these less invasive treatments. This trend is perfectly aligned with tumor ablation techniques, which can improve patient outcomes with shorter hospital stays and typically offer faster recovery times and fewer issues than traditional surgical techniques. These techniques' minimally invasive nature is particularly helpful for elderly patients or those with concomitant conditions who might not be the greatest candidates for surgery. The market has grown as a result of this patient-focused approach, which has raised the need for interventional tumor ablation.  

Technological advancements in ablation devices and imaging technologies have propelled market growth. Innovations in imaging guidance systems and efficient energy delivery have enhanced the precision and safety of tumor ablation treatments. The integration of artificial intelligence and machine learning further optimizes treatment outcomes. Expanding applications to diverse tumor types, including pancreatic, prostate, and breast cancers, bolster market growth as clinical trials validate these techniques' efficacy and safety. This continuous evolution positions ablation technologies as pivotal in cancer treatment.

Restraints and challenges:

Particularly in areas with low and moderate incomes, the high expense of sophisticated ablation equipment and procedures restricts accessibility. Further impeding industry expansion is the shortage of qualified healthcare workers. Oncologists' and interventional radiologists' inconsistent training and certification have an impact on the availability and quality of care. Additionally, the lack of skilled healthcare professionals hinders market growth.

Market Segmentation

The global interventional tumor ablation market share is classified into technology, application, and end-user. 

• The radiofrequency ablation segment secured a significant share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the technology, the global interventional tumor ablation market is separated into radiofrequency ablation, microwave ablation, cryoablation, and others. Among these, the radiofrequency ablation segment held a significant share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.  This significance share is attributed to its effectiveness and safety in treating different kinds of tumors. By producing localized heat with high-frequency electrical currents, RFA efficiently kills cancer cells. Particularly for liver and lung tumors, RFA is the favored option because to its accuracy and comparatively low risk. The market is expanding as a result of ongoing improvements in RFA devices, including as better electrode designs and real-time monitoring features, which are improving treatment results.

• The liver cancer segment held a significant share in 2023 and is expected to grow at a significant CAGR during the forecast period.       

Based on the application, the global interventional tumor ablation market is categorized as liver cancer, lung cancer, kidney cancer, bone metastasis, and others. Among these, the liver cancer segment held a significant share in 2023 and is expected to grow at a significant CAGR during the forecast period. Liver cancer is still one of the most common uses for tumor ablation procedures because of its high prevalence and frequently late-stage detection.  When surgery is not an option for a patient, ablation therapies provide a minimally invasive option that effectively controls tumors and improves patient outcomes.  Liver tumor ablation success rates have increased dramatically due to technological developments in imaging and needle insertion, which has fueled market expansion in these applications.

• The hospitals segment accounted for the highest share in 2023 and is anticipated to grow at a prominent CAGR during the forecast period.

Based on the end-user, the global interventional tumor ablation market is divided into hospitals, ambulatory surgical centers, specialty clinics, and others. Among these, the hospitals segment accounted for the highest share in 2023 and is anticipated to grow at a prominent CAGR during the forecast period. This segmental growth is driven by the presence of qualified healthcare professionals and the availability of cutting-edge medical facilities. Tumor ablation technology integration into oncology departments at hospitals, which are frequently the main locations for cancer detection and therapy, has been a major growth driver. This segment's supremacy is a result of continuous investments in hospital infrastructure and the uptake of cutting-edge medical technologies.

Regional Segment Analysis of the Global Interventional Tumor Ablation Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the global interventional tumor ablation market over the forecast period.

North America is projected to hold the largest share of the global interventional tumor ablation market over the forecast period. This region is propelled by increasing strong impact on cancer, high healthcare spending, and availability of advanced healthcare technology.  The presence of leading medical device companies, the making new innovation as well as quick adoption of innovative technology by the operating players and end users, also encourages market growth in this sector.  With its established healthcare system and strong emphasis on research and development, the United States notably holds a sizable portion of the North American market.

The Asia Pacific interventional tumor ablation market is expected to grow with the fastest CAGR during the forecasting period. The increasing impact of cancer significantly influences this regional growth, bettering healthcare infrastructure, and increased healthcare knowledge all have a big impact on this geographical expansion.  China, India, and Japan are leading the way in this expansion, investing heavily in healthcare infrastructure and placing an increasing focus on early cancer detection and treatment.  China is the market leader for interventional tumor ablation worldwide, thanks to its strong industrial base, encouraging legislation, and high local demand. In China, cancer was still a major health concern in 2024.  According to estimates, there were around 32.466 million new cases of cancer and 16.99 million deaths from the disease in the nation.  Radiofrequency ablation, microwave ablation, and cryoablation are among the advanced technology-based treatments that are required for these high incidence instances.  It contributed to the expansion of the interventional tumor ablation industry in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global interventional tumor ablation market along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Terumo Corporation
• Varian Medical Systems, Inc.
• Johnson & Johnson
• EDAP TMS S.A.
• BTG International Ltd.
• Hologic, Inc.
• Olympus Corporation
• Siemens Healthineers AG
• AngioDynamics, Inc.
• Merit Medical Systems, Inc.
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In July 2024, Varian Medical Systems, Inc. received 510k clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system. Designed for soft tissue ablation, IntelliBlate aims to provide clinicians with greater predictability, precision, and control during procedures. The system produces large, controlled spherical ablation zones and offers versatility with single or dual probes.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global interventional tumor ablation market based on the below-mentioned segments:

Global Interventional Tumor Ablation Market, By Technology

• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• Others

Global Interventional Tumor Ablation Market, By Application

• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Bone Metastasis
• Others

Global Interventional Tumor Ablation Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Global Interventional Tumor Ablation Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa